Australia has suggested vacationers who obtained the rabies vaccine Availab in India after November 1, 2023 to think about the vaccination invalid and to begin a brand new vaccination course. |Picture courtesy: Getty Photographs/iStockphoto
Indian Immunologicals Restricted (IIL), one in every of India’s main vaccine producers, on Saturday (December 27, 2025) issued a clarification concerning current reviews surrounding its human anti-rabies vaccine Availab.
The corporate added in an announcement that the counterfeiting incident referred to in relation to its rabies vaccine Availab (batch quantity KA24014 (manufacture date: March 2024, expiration date: February 2027)) had been recognized by early January 2025, strongly refuting over-cautious and misguided Australian Well being recommendation. He stated counterfeit badges are not on retailer cabinets.
Earlier this week, the Australian Immunization Technical Advisory Group issued a warning about counterfeit batches of the Availab vaccine being distributed in India from November 1, 2023.
The report stated Australian vacationers who obtained the Availab rabies vaccine in India after November 1, 2023, ought to take into account that vaccine to be ineffective and begin a brand new vaccination course.
Rabies is a viral zoonotic illness that impacts the central nervous system. Though signs are virtually at all times deadly, they’re preventable if medical care is sought instantly after publicity.
The corporate additional stated in an announcement that the vaccine has been manufactured by IIL since 2000 and has provided over 210 million doses throughout India and in 40 nations, persevering with to carry a 40% market share in India.
“In January 2025, IIL recognized packaging anomalies in a single specific batch (batch quantity KA 24014). The corporate instantly notified Indian regulators and regulation enforcement authorities, lodged a proper criticism and labored carefully with authorities to make sure immediate response,” it stated, including that this was an remoted incident and the counterfeit batch is not on retailer cabinets.
The IIL reassured healthcare staff and the general public that every one vaccines manufactured in India will likely be examined and shipped by the Central Pharmaceutical Laboratory (Authorities of India) earlier than being made out there on the market or administration.
“The provides provided by means of authorities businesses and approved distributors are protected and of normal high quality,” stated Sunil Tiwari, Vice President and High quality Management Officer, IIL.
The corporate additionally wrote to the Australian Technical Advisory Group on Immunization, stating that Availab, a purified cell culture-based rabies vaccine, is manufactured in accordance with relevant regulatory necessities, together with WHO Good Manufacturing Observe (GMP) and related pharmacy requirements.
It added that the product is meant to be used in each pre- and post-exposure prophylaxis in opposition to rabies and is provided by means of authorities procurement channels and the non-public healthcare sector.
“Each batch of vaccines manufactured in India is examined and launched by the Nationwide Management Laboratory (Central Pharmaceutical Laboratory), a pre-qualified laboratory in WHO and Geneva, underneath the purview of the Nationwide Regulatory Authority,” it added.
In the meantime, the Facilities for Illness Management and Prevention issued a well being alert for India and Haiti earlier this month after vacationers from these nations had been identified with rabies.
The advisory advises vacationers to keep away from contact with canines, cats and wild mammals in each nations.
